Colorectal Liver MetastasesNCT07760558
COLORS-Validate Study of Decision-Support Software for Surgical Sequencing in Colorectal Liver Metastases
An observational study of Colorectal Liver Metastases, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.
Trial summary
This study evaluates a surgical decision-support software designed to assist physicians in selecting the optimal surgical sequence for patients with colorectal cancer liver metastases. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Colorectal Liver Metastases
- What is being tested?
- Unaided Clinical Decision-Making and Software-Assisted Clinical Decision-Making
- How many people
- 12 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 30 Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: This study will enroll physicians from three tertiary academic medical centers in China, including hepatobiliary surgeons and colorectal surgeons with varying levels of clinical experience. Participants will be required to complete standardized simulation-based case evaluations involving surgical decision-making for colorectal cancer liver metastases. The study aims to assess changes in decision-making behavior, confidence, and usability of a decision-support software system.
Who may be able to join
- Licensed physicians specializing in hepatobiliary surgery or colorectal surgery
- At least 1 year of clinical experience after graduation
- Willing to participate in the simulation-based decision-making study
- Practicing at one of the participating tertiary academic hospitals
Who cannot join
- Not actively involved in clinical surgical decision-making
- Unable to complete all required simulation sessions
- Prior involvement in the development of the decision-support software
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Clinical Utility Evaluation of a Surgical Sequencing Decision-Support Software in Simulated Cases of Colorectal Liver Metastases: A Multicenter Prospective Study (COLORS-Validate Study)
This study evaluates a surgical decision-support software designed to assist physicians in selecting the optimal surgical sequence for patients with colorectal cancer liver metastases.
In this multicenter prospective simulation study, participating surgeons from multiple centers will review standardized clinical case scenarios. For each case, physicians will first make a surgical sequencing decision based on their own clinical judgment. They will then review the recommendation provided by the decision-support software and make a second decision if they choose to revise their initial plan.
Read more
The study will assess whether the software influences clinical decision-making, including changes in surgical strategy, decision confidence, decision time, and agreement with software recommendations. Physician user experience will also be evaluated using standardized questionnaires, including system usability and cognitive workload scales.
The goal of this study is to determine the clinical utility and usability of the decision-support software in improving surgical decision-making consistency and supporting clinical reasoning in colorectal liver metastases cases.
Read the detailed description
The selection of surgical sequencing-whether to resect the primary tumor first or the liver metastases first-in patients with colorectal cancer liver metastases (CRLM) undergoing synchronous resection represents a critical and highly complex decision in current clinical practice. With the advancement of systemic therapies and surgical techniques, an increasing number of patients with initially unresectable CRLM have gained the opportunity for surgical treatment. However, due to substantial heterogeneity among patients in terms of tumor burden, biological behavior of the disease, and overall physical condition, no unified standard currently exists for determining the optimal surgical sequence. Existing studies comparing different surgical strategies have yielded inconsistent prognostic results, and most are based on retrospective analyses lacking consistent conclusions and clear stratification criteria. Consequently, in real-world clinical practice, such decisions rely heavily on physician experience and institutional preference, resulting in considerable inter-physician variability and uncertainty. This scenario, characterized by the absence of a clearly optimal strategy, renders the decision-making process inherently a form of decision-making under uncertainty.
Based on this context, we previously developed, using multicenter retrospective data, two multi-outcome predictive models corresponding to different surgical strategies. These models integrate postoperative major complications, Comprehensive Complication Index (CCI), progression-free survival (PFS), and overall survival (OS), and have been externally validated. However, in real-world clinical decision-making, the central challenge faced by surgeons is not merely the prediction of a single outcome, but rather the need to balance multiple competing outcomes. For example, one surgical strategy may be associated with a lower risk of postoperative complications but limited long-term survival benefit, whereas another may involve higher perioperative risk in exchange for improved oncological outcomes. This inherent tension among multidimensional outcomes transforms clinical decision-making into a multi-objective decision-making problem, rather than a simple comparison of a single endpoint.
In current practice, such trade-offs across outcomes are typically based on physicians' experiential judgment, whereby the relative importance of different outcomes is implicitly weighted. However, this weighting process lacks explicit representation and standardized criteria, and is prone to influence by individual experience, risk preference, and institutional norms, thereby leading to substantial variability and inconsistency in decision-making. To address this key limitation, the present study further constructs a structured multi-outcome weighting framework using the Delphi method combined with the analytic hierarchy process (AHP). This approach establishes the relative importance of different clinical outcomes through expert consensus and translates it into a quantifiable weighting system, thereby enabling the integration of multidimensional predictive results into a comparable composite score. Based on this framework, we developed a decision-support software system capable of simultaneously providing individualized multi-outcome predictions and composite reference scores, transforming the previously experience-dependent implicit trade-off process into a transparent, interpretable, and standardized decision-support process.
Nevertheless, the establishment of predictive models and weighting frameworks does not necessarily translate into practical clinical value. For decision-support systems, focusing solely on predictive performance is insufficient to reflect their real-world clinical utility. More importantly, it is necessary to evaluate whether such systems can influence physician decision-making behavior under uncertainty, reduce unnecessary variability, and provide a structured reference framework for decision-making. In addition, because clinical decision-making involves counterfactual comparisons (i.e., potential outcomes under alternative strategies for the same patient cannot be simultaneously observed), traditional outcome-based evaluation methods have inherent limitations. Therefore, it is necessary to adopt a model-informed standardized reference framework to evaluate the impact of AI assistance at the level of decision behavior.
Based on the above considerations, this study adopts a multicenter, prospective crossover simulation design to systematically evaluate the clinical utility of the decision-support system in a standardized setting. The evaluation focuses on the following two dimensions:
- From a scientific decision perspective: whether the system alters physician decision behavior, improves decision consistency, and reduces variability;
- From a human factors perspective: whether the system affects cognitive load, decision confidence, and user experience.
This study extends AI evaluation beyond predictive performance toward its influence on decision-making behavior, with a particular focus on the human-AI collaborative decision-making process in uncertain clinical scenarios.
- Conditions
- Colorectal Liver Metastases
- Being tested
- Unaided Clinical Decision-Making, Software-Assisted Clinical Decision-Making
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Unaided Clinical Decision-MakingOther
Usual Clinical Decision-Making (Without Decision Support Software)
Software-Assisted Clinical Decision-MakingOther
Physicians make surgical sequencing decisions after reviewing recommendations generated by the decision-support software, including weighted scores and predicted outcomes.
| Study group | Role | What they receive |
|---|---|---|
| Unaided Clinical Decision-Making | Physicians make surgical sequencing decisions based on routine clinical judgment without decision-support software. Receives: Other: Unaided Clinical Decision-Making | |
| Decision-Support Software-Assisted Decision-Making | Physicians make surgical sequencing decisions after reviewing recommendations from the decision-support software. Receives: Other: Software-Assisted Clinical Decision-Making |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Surgical Decision-Making Between Software-Assisted and Non-Assisted Conditions
The primary outcome is the proportion of cases in which physicians change their surgical sequencing decision after reviewing decision-support software recommendations compared with their initial unaided decision.
Measured: During each simulated case evaluation session
Secondary outcomes (3)
Software utilization outcomes
Software adoption rate (agreement between final decision and software recommendation); Post-change adoption rate among changed decisions
Measured: During each simulated case evaluation session
Decision performance outcomes
Decision-making time (seconds per case); Inter-group comparison between unaided and software-assisted conditions
Measured: During each simulated case evaluation session
Human factors outcomes
Decision confidence score (5-point Likert scale)
Measured: During each simulated case evaluation session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2026
- Study start1 Sep 2026 (estimated)
- Primary completion30 Sep 2026 (estimated)
- Study completion30 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Colorectal Liver MetastasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Hong Zhao, MD, Study chair, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07760558
- Sponsor's protocol ID
- NCC-023039
- Status last verified
- Aug 2026
- First submitted
- 23 Jul 2026
- Last updated
- 12 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be publicly shared because of participant confidentiality, institutional data-protection requirements, and the potential risk of re-identification given the characteristics and size of the study population. Aggregate study results will be reported in peer-reviewed publications.
Publications
Chen Q, Chen J, Deng Y, Bi X, Zhao J, Zhou J, Huang Z, Cai J, Xing B, Li Y, Li K, Zhao H. Personalized prediction of postoperative complication and survival among Colorectal Liver Metastases Patients Receiving Simultaneous Resection using machine learning approaches: A multi-center study. Cancer Lett. 2024 Jul 1;593:216967. doi: 10.1016/j.canlet.2024.216967. Epub 2024 May 18.
PubMed 38768679Chen Q, Tong J, Deng Y, Bi X, Li Y, Li K, Zhao H. Impact of an AI prognostic tool on clinician performance in colorectal liver metastases. NPJ Digit Med. 2026 Apr 8;9(1):432. doi: 10.1038/s41746-026-02606-5.
PubMed 41951838Chen Q, Deng Y, Wang K, Li Y, Bi X, Li K, Zhao H. Dynamic Prognostic Models for Colorectal Cancer With Liver Metastases. JAMA Netw Open. 2025 Aug 1;8(8):e2529093. doi: 10.1001/jamanetworkopen.2025.29093.
PubMed 40864468
Study at a glance
From the registry record, last updated by the sponsor on 12 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Utility Evaluation of a Surgical Sequencing Decision-Support Software in Simulated Cases of Colorectal Liver Metastases: A Multicenter Prospective Study (COLORS-Validate Study)
- ClinicalTrials.gov ID
- NCT07760558
- Acronym / sponsor ID
- NCC-023039
- Conditions
- Colorectal Liver Metastases
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical SciencesUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 30 Oct 2026 (estimated)
- First posted
- 12 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates a surgical decision-support software designed to assist physicians in selecting the optimal surgical sequence for patients with colorectal cancer liver metastases.
In this multicenter prospective simulation study, participating surgeons from multiple centers will review standardized clinical case scenarios. For each case, physicians will first make a surgical sequencing decision based on their own clinical judgment. They will then review the recommendation provided by the decision-support software and make a second decision if they choose to revise their initial plan.
The study will assess whether the software influences clinical decision-making, including changes in surgical strategy, decision confidence, decision time, and agreement with software recommendations. Physician user experience will also be evaluated using standardized questionnaires, including system usability and cognitive workload scales.
The goal of this study is to determine the clinical utility and usability of the decision-support software in improving surgical decision-making consistency and supporting clinical reasoning in colorectal liver metastases cases.
Detailed description
The selection of surgical sequencing-whether to resect the primary tumor first or the liver metastases first-in patients with colorectal cancer liver metastases (CRLM) undergoing synchronous resection represents a critical and highly complex decision in current clinical practice. With the advancement of systemic therapies and surgical techniques, an increasing number of patients with initially unresectable CRLM have gained the opportunity for surgical treatment. However, due to substantial heterogeneity among patients in terms of tumor burden, biological behavior of the disease, and overall physical condition, no unified standard currently exists for determining the optimal surgical sequence. Existing studies comparing different surgical strategies have yielded inconsistent prognostic results, and most are based on retrospective analyses lacking consistent conclusions and clear stratification criteria. Consequently, in real-world clinical practice, such decisions rely heavily on physician experience and institutional preference, resulting in considerable inter-physician variability and uncertainty. This scenario, characterized by the absence of a clearly optimal strategy, renders the decision-making process inherently a form of decision-making under uncertainty.
Based on this context, we previously developed, using multicenter retrospective data, two multi-outcome predictive models corresponding to different surgical strategies. These models integrate postoperative major complications, Comprehensive Complication Index (CCI), progression-free survival (PFS), and overall survival (OS), and have been externally validated. However, in real-world clinical decision-making, the central challenge faced by surgeons is not merely the prediction of a single outcome, but rather the need to balance multiple competing outcomes. For example, one surgical strategy may be associated with a lower risk of postoperative complications but limited long-term survival benefit, whereas another may involve higher perioperative risk in exchange for improved oncological outcomes. This inherent tension among multidimensional outcomes transforms clinical decision-making into a multi-objective decision-making problem, rather than a simple comparison of a single endpoint.
In current practice, such trade-offs across outcomes are typically based on physicians' experiential judgment, whereby the relative importance of different outcomes is implicitly weighted. However, this weighting process lacks explicit representation and standardized criteria, and is prone to influence by individual experience, risk preference, and institutional norms, thereby leading to substantial variability and inconsistency in decision-making. To address this key limitation, the present study further constructs a structured multi-outcome weighting framework using the Delphi method combined with the analytic hierarchy process (AHP). This approach establishes the relative importance of different clinical outcomes through expert consensus and translates it into a quantifiable weighting system, thereby enabling the integration of multidimensional predictive results into a comparable composite score. Based on this framework, we developed a decision-support software system capable of simultaneously providing individualized multi-outcome predictions and composite reference scores, transforming the previously experience-dependent implicit trade-off process into a transparent, interpretable, and standardized decision-support process.
Nevertheless, the establishment of predictive models and weighting frameworks does not necessarily translate into practical clinical value. For decision-support systems, focusing solely on predictive performance is insufficient to reflect their real-world clinical utility. More importantly, it is necessary to evaluate whether such systems can influence physician decision-making behavior under uncertainty, reduce unnecessary variability, and provide a structured reference framework for decision-making. In addition, because clinical decision-making involves counterfactual comparisons (i.e., potential outcomes under alternative strategies for the same patient cannot be simultaneously observed), traditional outcome-based evaluation methods have inherent limitations. Therefore, it is necessary to adopt a model-informed standardized reference framework to evaluate the impact of AI assistance at the level of decision behavior.
Based on the above considerations, this study adopts a multicenter, prospective crossover simulation design to systematically evaluate the clinical utility of the decision-support system in a standardized setting. The evaluation focuses on the following two dimensions:
- From a scientific decision perspective: whether the system alters physician decision behavior, improves decision consistency, and reduces variability;
- From a human factors perspective: whether the system affects cognitive load, decision confidence, and user experience.
This study extends AI evaluation beyond predictive performance toward its influence on decision-making behavior, with a particular focus on the human-AI collaborative decision-making process in uncertain clinical scenarios.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Unaided Clinical Decision-Making | – | Other: Unaided Clinical Decision-MakingPhysicians make surgical sequencing decisions based on routine clinical judgment without decision-support software. |
| Decision-Support Software-Assisted Decision-Making | – | Other: Software-Assisted Clinical Decision-MakingPhysicians make surgical sequencing decisions after reviewing recommendations from the decision-support software. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- This study will enroll physicians from three tertiary academic medical centers in China, including hepatobiliary surgeons and colorectal surgeons with varying levels of clinical experience. Participants will be required to complete standardized simulation-based case evaluations involving surgical decision-making for colorectal cancer liver metastases. The study aims to assess changes in decision-making behavior, confidence, and usability of a decision-support software system.
Key inclusion criteria (4 listed)
- Licensed physicians specializing in hepatobiliary surgery or colorectal surgery
- At least 1 year of clinical experience after graduation
- Willing to participate in the simulation-based decision-making study
- Practicing at one of the participating tertiary academic hospitals
Key exclusion criteria (3 listed)
- Not actively involved in clinical surgical decision-making
- Unable to complete all required simulation sessions
- Prior involvement in the development of the decision-support software
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Unaided Clinical Decision-MakingUsual Clinical Decision-Making (Without Decision Support Software) | Other | Unaided Clinical Decision-Making |
| Software-Assisted Clinical Decision-MakingPhysicians make surgical sequencing decisions after reviewing recommendations generated by the decision-support software, including weighted scores and predicted outcomes. | Other | Decision-Support Software-Assisted Decision-Making |
Primary outcome
Change in Surgical Decision-Making Between Software-Assisted and Non-Assisted Conditions
Time frame: During each simulated case evaluation session
The primary outcome is the proportion of cases in which physicians change their surgical sequencing decision after reviewing decision-support software recommendations compared with their initial unaided decision.
3 secondary outcomes
Software utilization outcomes
Time frame: During each simulated case evaluation session
Decision performance outcomes
Time frame: During each simulated case evaluation session
Human factors outcomes
Time frame: During each simulated case evaluation session
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2026.
- Background: PubMed 38768679Chen Q, Chen J, Deng Y, Bi X, Zhao J, Zhou J, Huang Z, Cai J, Xing B, Li Y, Li K, Zhao H. Personalized prediction of postoperative complication and survival among Colorectal Liver Metastases Patients Receiving Simultaneous Resection using machine learning approaches: A multi-center study. Cancer Lett. 2024 Jul 1;593:216967. doi: 10.1016/j.canlet.2024.216967. Epub 2024 May 18.
- Background: PubMed 41951838Chen Q, Tong J, Deng Y, Bi X, Li Y, Li K, Zhao H. Impact of an AI prognostic tool on clinician performance in colorectal liver metastases. NPJ Digit Med. 2026 Apr 8;9(1):432. doi: 10.1038/s41746-026-02606-5.
- Background: PubMed 40864468Chen Q, Deng Y, Wang K, Li Y, Bi X, Li K, Zhao H. Dynamic Prognostic Models for Colorectal Cancer With Liver Metastases. JAMA Netw Open. 2025 Aug 1;8(8):e2529093. doi: 10.1001/jamanetworkopen.2025.29093.
- Individual participant dataSharing planned: No. Individual participant data will not be publicly shared because of participant confidentiality, institutional data-protection requirements, and the potential risk of re-identification given the characteristics and size of the study population. Aggregate study results will be reported in peer-reviewed publications.
Related trials for Colorectal Liver Metastases
RecruitingPhase 2
SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
Colorectal Cancer, Liver Metastasis Colon Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 1
A Study of MGC026 in Participants With Advanced Solid Tumors
Advanced Solid Tumor, Advanced Cancer
Active, not recruitingPhase 2
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Metastatic Colorectal Cancer
Recruiting
TheraSphere Japan Pre-Market Study
Liver Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hong Zhao, MD study chair
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Liver Metastases, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hong Zhao, MD (+86 01087787100, tongjinliang0202@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Surgical Decision-Making Between Software-Assisted and Non-Assisted Conditions (time frame: During each simulated case evaluation session). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07760558, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.